https://www.selleckchem.com/products/lgk-974.html
156, P=0.023) and progesterone receptor negativity (OR 2.762, P=0.008) independently predicted breast pCR, while ductal carcinoma (OR 3.203, P=0.03 and grade 3 disease (OR 2.788, P=0.018) predicted axillary pCR. Both breast and axillary pCR predicted enhanced DFS (Hazard Ratio (HR) 0.470 HR 0.449) and OS (HR 0.383 HR 0.307). Axillary pCR independently predicted improved OS (HR 0.326). pCR is sensitive biomarker and surrogate to survival outcomes in HER2+ breast cancer. Patients likely to achieve pCR may be predicted from t
Like
Comment
Share
